Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH
Founder-led company
Amphastar Pharmaceuticals stock price today
$30.32
-7.47
-19.79%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Amphastar Pharmaceuticals stock price monthly change
-2.33%
month
Amphastar Pharmaceuticals stock price quarterly change
-2.33%
quarter
Amphastar Pharmaceuticals stock price yearly change
-39.93%
year
Amphastar Pharmaceuticals key metrics
Market Cap | 1.86B |
Enterprise value | 1.90B |
P/E | 22.25 |
EV/Sales | 3.81 |
EV/EBITDA | 13.09 |
Price/Sales | 3.92 |
Price/Book | 3.70 |
PEG ratio | 0.49 |
EPS | 3.2 |
Revenue | 676.20M |
EBITDA | 239.31M |
Income | 154.69M |
Revenue Q/Q | 22.72% |
Revenue Y/Y | 30.38% |
Profit margin | 18.31% |
Oper. margin | 21.54% |
Gross margin | 49.87% |
EBIT margin | 21.54% |
EBITDA margin | 35.39% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAmphastar Pharmaceuticals stock price history
Amphastar Pharmaceuticals stock forecast
Amphastar Pharmaceuticals financial statements
| Jun 2023 | 145.71M | 26.12M | 17.93% |
|---|---|---|---|
| Sep 2023 | 180.55M | 49.22M | 27.26% |
| Dec 2023 | 178.10M | 36.16M | 20.31% |
| Mar 2024 | 171.83M | 43.17M | 25.13% |
| Mar 2024 | 171.83M | 43.17M | 25.13% |
|---|---|---|---|
| Sep 2025 | 229.7M | 62.02M | 27% |
| Oct 2025 | 228.9M | 62.02M | 27.1% |
| Dec 2025 | 215.9M | 56.19M | 26.03% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1378266000 | 789.03M | 57.25% |
|---|---|---|---|
| Sep 2023 | 1544633000 | 949.49M | 61.47% |
| Dec 2023 | 1512912000 | 873.49M | 57.74% |
| Mar 2024 | 1574317000 | 901.96M | 57.29% |
| Jun 2023 | 54.92M | -508.58M | 428.11M |
|---|---|---|---|
| Sep 2023 | 64.33M | -31.15M | 86.61M |
| Dec 2023 | 23.86M | -103.04M | -47.08M |
| Mar 2024 | 55.29M | 15.23M | -13.57M |
Amphastar Pharmaceuticals alternative data
| Aug 2023 | 1,615 |
|---|---|
| Sep 2023 | 1,615 |
| Oct 2023 | 1,615 |
| Nov 2023 | 1,615 |
| Dec 2023 | 1,615 |
| Jan 2024 | 1,615 |
| Feb 2024 | 1,615 |
| Mar 2024 | 1,761 |
| Apr 2024 | 1,761 |
| May 2024 | 1,761 |
| Jun 2024 | 1,761 |
| Jul 2024 | 1,761 |
Amphastar Pharmaceuticals other data
37.07%
-18.09%
of AMPH is owned by hedge funds
146
-58
19.43M
-9.68M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 351686 |
| Feb 2024 | 0 | 500 |
| Mar 2024 | 0 | 31136 |
| Apr 2024 | 0 | 500 |
| May 2024 | 0 | 500 |
| Jun 2024 | 0 | 7096 |
| Jul 2024 | 0 | 10282 |
| Aug 2024 | 0 | 21101 |
| Sep 2024 | 0 | 6000 |
| Nov 2024 | 0 | 24533 |
| Dec 2024 | 0 | 25000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | ZHOU RONG officer: SENIOR E.. | Common Stock | 8,000 | $11.33 | $90,640 | ||
Sale | ZHOU RONG officer: SENIOR E.. | Common Stock | 8,000 | $45.23 | $361,840 | ||
Option | ZHOU RONG officer: SENIOR E.. | Employee Stock Option (right to buy) | 8,000 | $11.33 | $90,640 | ||
Option | ZHOU RONG officer: SENIOR E.. | Common Stock | 7,000 | $11.33 | $79,310 | ||
Sale | ZHOU RONG officer: SENIOR E.. | Common Stock | 7,000 | $44.43 | $310,975 | ||
Option | ZHOU RONG officer: SENIOR E.. | Employee Stock Option (right to buy) | 7,000 | $11.33 | $79,310 | ||
Option | PRINS RICHARD K director | Common Stock | 10,000 | $19.52 | $195,200 | ||
Sale | PRINS RICHARD K director | Common Stock | 10,000 | $43.77 | $437,700 | ||
Option | PRINS RICHARD K director | Stock Option (right to buy) | 10,000 | $19.52 | $195,200 | ||
Option | ZHOU RONG officer: SENIOR E.. | Common Stock | 6,893 | $14.95 | $103,050 |
| Patent |
|---|
Application Filling date: 25 Sep 2019 Issue date: 9 Jul 2020 |
Application HIGH-PURITY INHALABLE PARTICLES OF INSULIN AND INSULIN ANALOGUES, AND HIGH-EFFICIENCY METHODS OF MANUFACTURING THE SAME Filling date: 28 Aug 2019 Issue date: 26 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Yongfeng Zhang (1947) Co-founder, Pres, Chief Executive Officer, Chief Scientific Officer & Director | $1,980,000 |
Dr. Ziping Luo (1950) Chairman, Chief Scientist & Chief Operating Officer | $1,230,000 |
Mr. William J. Peters M.B.A. (1968) Chief Financial Officer, Treasurer & Executive Vice President of Fin. | $1,090,000 |
| Mr. Rong Zhou (1959) Executive Vice President of Production Center | $768,660 |
Mr. Jacob Liawatidewi M.B.A. (1974) Executive Vice President of Corporation Admin. Center, Sales & Marketing and Corporation Sec. | $749,570 |
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Amphastar Pharmaceuticals: Profitable Pharma With Strong Growth
Amphastar Pharmaceuticals: Great Growth At A High Price
Amphastar: Dip, But No Slip, Rebound Playbook (Rating Upgrade)
Amphastar Pharma: A Company Growing Quickly As Acquisitions Likely Fuel Growth
Amphastar: Generating High Incremental Growth From Tidy Earnings Reinvestment
Amphastar: Growth Remains Intact
MDA Breakout Stocks Week 44 - November 2022: Short-Term Picks To Give You An Edge
-
What's the price of Amphastar Pharmaceuticals stock today?
One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $30.32.
-
When is Amphastar Pharmaceuticals's next earnings date?
Unfortunately, Amphastar Pharmaceuticals's (AMPH) next earnings date is currently unknown.
-
Does Amphastar Pharmaceuticals pay dividends?
No, Amphastar Pharmaceuticals does not pay dividends.
-
How much money does Amphastar Pharmaceuticals make?
Amphastar Pharmaceuticals has a market capitalization of 1.86B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 29.14% to 644.4M US dollars.
-
What is Amphastar Pharmaceuticals's stock symbol?
Amphastar Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AMPH".
-
What is Amphastar Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Amphastar Pharmaceuticals?
Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Amphastar Pharmaceuticals's key executives?
Amphastar Pharmaceuticals's management team includes the following people:
- Dr. Yongfeng Zhang Co-founder, Pres, Chief Executive Officer, Chief Scientific Officer & Director(age: 78, pay: $1,980,000)
- Dr. Ziping Luo Chairman, Chief Scientist & Chief Operating Officer(age: 75, pay: $1,230,000)
- Mr. William J. Peters M.B.A. Chief Financial Officer, Treasurer & Executive Vice President of Fin.(age: 57, pay: $1,090,000)
- Mr. Rong Zhou Executive Vice President of Production Center(age: 66, pay: $768,660)
- Mr. Jacob Liawatidewi M.B.A. Executive Vice President of Corporation Admin. Center, Sales & Marketing and Corporation Sec.(age: 51, pay: $749,570)
-
Is Amphastar Pharmaceuticals founder-led company?
Yes, Amphastar Pharmaceuticals is a company led by its founder Dr. Yongfeng Zhang.
-
How many employees does Amphastar Pharmaceuticals have?
As Jul 2024, Amphastar Pharmaceuticals employs 1,761 workers.
-
When Amphastar Pharmaceuticals went public?
Amphastar Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 25 Jun 2014.
-
What is Amphastar Pharmaceuticals's official website?
The official website for Amphastar Pharmaceuticals is amphastar.com.
-
Where are Amphastar Pharmaceuticals's headquarters?
Amphastar Pharmaceuticals is headquartered at 11570 6th Street, Rancho Cucamonga, CA.
-
How can i contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals's mailing address is 11570 6th Street, Rancho Cucamonga, CA and company can be reached via phone at +90 99809484.
Amphastar Pharmaceuticals company profile:
Amphastar Pharmaceuticals, Inc.
amphastar.comExchange:
NASDAQ
Full time employees:
1,761
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
11570 6th Street
Rancho Cucamonga, CA 91730
Rancho Cucamonga, CA 91730
CIK: 0001297184
ISIN: US03209R1032
CUSIP: 03209R103
